[PDF] Top 20 Effect of Neoadjuvant Chemotherapy in Advanced Ovarian Carcinoma

... received chemotherapy and then were able to undergo cytoreductive surgery, had a survival that was quite similar to those patients who initially had large volume disease present in the upper abdomen or Stage IV ... See full document

... MANUSCRIPT Effect of Wilms tumor histology on response to neoadjuvant chemotherapy Wilms tumor is often large and ...Preoperative chemotherapy is systematically used in The International ... See full document

... a histological diagnosis and objectively documents the extent of the disease. At the same time it identifies patients who can be optimally debulked, thus not denying the pos- sible benefit of such a procedure. The issue ... See full document

... of neoadjuvant chemotherapy include an increased rate of optimal debulking, less extensive surgery, reduced blood loss, lower morbidity, shortened hospital stay, and improved quality of ... See full document

... Lobular carcinoma Invasive lobular carcinoma is the second most common histologic type after ductal carcinoma, accounting for 5-10% of all breast ...ductal carcinoma, except that the extent of ... See full document

... significant. This was unexpected, because we hypothesized that TURBT CIS would not only result in decreased pCR rates but would also result in decreased PFS and OS. A potential explanation for the longer than expected ... See full document

... r-GPx. Neoadjuvant chemotherapy is currently a common approach for treatment of cancer ...to chemotherapy, its benefit is only realised in a small number of patients who achieve optimal tumour burden ... See full document

... the effect of neoadjuvant therapy on the number of complications following secondary cytoreduc- tion compared with primary surgery tend to prevail, often leading to a misguided belief that the ... See full document

... These results suggest that, R0 resection at PDS was as- sociated with the best prognosis. Debulking to RD < 1 cm provides a smaller but still significant benefit for pa- tients with PDS. For these patients, aggressive ... See full document

... vivo. In NACT group, the intraoperative blood loss and amount of ascites were markedly less, and the operation time and length of hospitalization were markedly shorter than those in control group. The above findings ... See full document

... treating advanced ovarian cancer and also adjusted costs for patient and clinical ...adverse effect costs (tangible and intangible) associated with extended cancer treatment cannot be ... See full document

... A comparison of pre- and postoperative tumor staging demonstrates a surprisingly low accuracy of implemented diagnostics. In the group without CTx, only 7 cases of 15 diagnosed stage III tumors were verified ... See full document

... It is important to reduce the incidence of platinum-resistance in the good responder patient subgroup treated with NAC. In the models for predicting platinum-resistance, a low NPV increases the possibility of ... See full document

... Le T et al 61 patients who have undergone IDS following NACT.All surgeries performed after 3 cycles of Platinum / Taxol combination chemotherapy.80% had a residual disease status of 2cm or less after surgery. ... See full document

... starting Neoadjuvant Chemotherapy so that original tumor site can be located if a complete CR is achieved to neoadjuvant ...to neoadjuvant chemotherapy BCT is generally not considered ... See full document

... cell carcinoma of esophagus, Karnofsky performance status > 70%, age younger than 70, tnM stage IIb, IIIA, IIIb, ...to chemotherapy like uncontrolled hypertension, past history of Myocardial infarction; ... See full document

... Dovepress aeg-1 expression in advanced eOc Some clues that help to explain the mechanisms by which AEG-1 mediates chemotherapy resistance have recently been discovered. These clues include evidence showing ... See full document

... with advanced ovarian cancer [ 12 – 16 ...of advanced-stage ovarian cancer patients [ 12 ], while Colombo et ...NAC: neoadjuvant chemotherapy; POAC: postoperative adjuvant ... See full document

... locally advanced disease (FIGO Stage IIB, III and IVA) and offers an alternative to radical surgery for patients with tumor larger than 4 cms confined to the cervix (Stage IB ... See full document

... Epithelial ovarian cancer includes a diverse group of hetero- geneous neoplasms, with the five main subtypes being HGSC, endometrioid, clear cell, mucinous, and ...although ovarian cancer is often clini- ... See full document